ABSTRACT
To cater to the gradually increasing sizes of ships, several traditional container ports in East Asia built deep-water wharves to attract shipping carriers to berth, a decision that is considered highly reasonable because it allows for shipping carriers to gain a cost advantage. For traditional Far East/Europe (F/E) trunk routes, shipping carriers must deploy vessels that are large enough at hub ports to maintain low transshipment costs. However, for a port to attract shipping carriers, it should be able to first meet the cargo demand of these carriers. The port would also need to improve the loading ratio to enjoy the cost advantage. Simultaneously, the port should leverage the loading and unloading efficiency of the terminal to gain a competitive advantage. Although the port congestion observed at the F/E trunk during COVID-19 was not as serious as that in North American ports, it was sufficient to affect the route deployment and port selection decisions of shipping carriers. Currently, because the size of container carriers is the most critical factor in the reduction of shipping costs, as demonstrated in this study, the upsizing trend of container ships is regarded as a highly relevant aspect in the deployment of trunk routes and the selection of hub ports. © 2023 National Taiwan Ocean University.
ABSTRACT
Background There are a growing number of case reports of various autoimmune diseases occurring after COVID-19, yet there is no large-scale population-based evidence to support this potential association. This study provides a closer insight into the association between COVID-19 and autoimmune diseases and reveals discrepancies across sex, age, and race of participants.Methods This is a retrospective cohort study based on the TriNetX U.S. Collaborative Network. In the test-negative design, cases were participants with positive polymerase chain reaction (PCR) test results for SARS-CoV-2, while controls were participants who tested negative and were not diagnosed with COVID-19 throughout the follow-up period. Patients with COVID-19 and controls were propensity score-matched (1: 1) for age, sex, race, adverse socioeconomic status, lifestyle-related variables, and comorbidities. The primary endpoint is the incidence of newly recorded autoimmune diseases. Adjusted hazard ratios (aHRs) and 95% confident intervals (CIs) of autoimmune diseases were calculated between propensity score-matched groups with the use of Cox proportional-hazards regression models.Findings Between January 1st, 2020 and December 31st, 2021, 3,814,479 participants were included in the study (888,463 cases and 2,926,016 controls). After matching, the COVID-19 cohort exhibited significantly higher risks of rheumatoid arthritis (aHR:2.98, 95% CI:2.78-3.20), ankylosing spondylitis (aHR:3.21, 95% CI:2.50-4.13), systemic lupus erythematosus (aHR:2.99, 95% CI:2.68-3.34), dermatopolymyositis (aHR:1.96, 95% CI:1.47-2.61), systemic sclerosis (aHR:2.58, 95% CI:2.02-3.28), Sjogren's syndrome (aHR:2.62, 95% CI:2.29-3.00), mixed connective tissue disease (aHR:3.14, 95% CI:2.26-4.36), Behcet's disease (aHR:2.32, 95% CI:1.38-3.89), polymyalgia rheumatica (aHR:2.90, 95% CI:2.36-3.57), vasculitis (aHR:1.96, 95% CI:1.74-2.20), psoriasis (aHR:2.91, 95% CI:2.67-3.17), inflammatory bowel disease (aHR:1.78, 95%CI:1.72-1.84), celiac disease (aHR:2.68, 95% CI:2.51-2.85), type 1 diabetes mellitus (aHR:2.68, 95%CI:2.51-2.85) and mortality (aHR:1.20, 95% CI:1.16-1.24).Interpretation COVID-19 is associated with a different degree of risk for various autoimmune diseases. Given the large sample size and relatively modest effects these findings should be replicated in an independent dataset. Further research is needed to better understand the underlying mechanisms.Funding Kaohsiung Veterans General Hospital (KSVGH111-113).
ABSTRACT
Exercise at home has already been a common behavior in the current world, especially in the post-COVID-19 era, even some athletes need to do physical fitness at home to keep their state due to the quarantine. So, the importance of online physical training and evaluation is highly increasing. In this work, we build an online 8-form Tai Chi Chuan (TCC) training and evaluation system, which provides a platform for coaches and users to conduct TCC training and evaluation online. Coaches formulate an evaluation rule and upload coaching videos to the platform, then users watch videos online and submit their own recordings, finally, users will get a score of their recordings. To complete this task, we propose a video capture method to record users' sports exercise videos from different perspectives, construct a 3D pose estimation model to identify human pose from captured video, and propose an evaluation model which can judge users' performance and assign a score to each video. To test our proposed models, we make a dataset consisting of key pose frames of TCC, and the key pose frames are extracted from users' TCC exercise videos. We use the dataset to train our models and assign scores to key poses, then compare the results with scores given by professional TCC players. In addition, we add all key pose scores from every single user together and obtain the whole score of an exercise video. The experiment results show that the error between scores assigned by our models and scores given by professional players does not exceed 1.6 in most scoring of a whole exercise video, and Root Mean Square Error (RMSE) is about 0.75 in the scoring of each key pose. © 2022 IEEE.
ABSTRACT
Background: To investigate the common symptoms after Covid-19 infection, characteristics of adverse events after vaccination, changes in clinical manifestations related to Neurofibromatosis type 1 (NF1), as well as the current vaccination status and factors related to vaccine hesitation among NF1 patients, in order to provide a basis for scientific protection and vaccine acceptance in NF1 individuals in the new phase of pandemic management. Method(s): From December 29, 2022, to January 10, 2023, we conducted a self-assessment questionnaire survey among diagnosed NF1 patients. General data were provided including sex, age, main clinical presentations, and current treatment. This study mainly focused on the infection and vaccination status of Covid-19 among these patients with NF1. The data were statistically analyzed using SPSS26.0 software. Result(s): Of the 250 questionnaires distributed, 226 were valid. Among the 164 patients (72.6%) with Covid-19 infection, the most common infection symptoms and incidence of patients were not significantly different from those in the normal population (P>0.05), but the incidence of symptoms such as nasal congestion, headache, myalgia, sore throat, abdominal pain, diarrhea, and eye discomfort was higher than that in the normal population (P<0.05), and no severe infection was observed;186 patients (82.3%) had completed the Covid-19 vaccination, and more than half of those who were not vaccinated had no plans for vaccination. Among the vaccinated patients, there was no significant difference in the incidence of adverse events, such as fever, pain, redness, and swelling at the injection site after vaccination, compared to the normal population (P>0.05), but the incidence of fatigue and headache was higher in NF1 patients (P<0.001). Most patients with NF1 believe that there is no significant progressive change in NF1-related clinical manifestations after Covid-19 infection and vaccination. Conclusion(s): Currently, some NF1 patients appear to be worried about the evolution of their disease after Covid-19 infection in the face of large fluctuations in the pandemic situation, and some patients hesitate to receive the vaccine due to their special disease condition. Thus, clinical trials should be conducted to develop a refined pandemic response and vaccination program for this special group.Copyright © 2023 China Medical Cosmetology Press Co. Ltd.
ABSTRACT
The COVID19 pandemic and the multiple phases of MCOs have caused a massive impact on informal economic activities. The operators have to transform their economic activities from physical to online platforms. However, changing the economic activity platform is not as easy as it may seem. It requires the operators to acquire new skills. Therefore, this paper intends to unleash the challenges faced by the operators in transforming their businesses from physical to online platforms. This study employs a qualitative approach to achieve the objective of this study. The main respondent in this study is the fishermen's community. Three parties are involved in this study: the operators (fishermen and the entrepreneurs), the government, and the academia. Findings show that the triple helix model provides a positive platform for operators to continue their businesses online. The bonding between these three parties provides a new path for the informal operators to sustain their well-being and better quality of life. © 2022 by MIP.
ABSTRACT
Coronavirus disease 2019 (COVID-19) epidemics have spread worldwide in recent years by its extreme contagiousness. The diagnosis of COVID-19 is crucial in the prevention, control, and treatment procedure. Deep learning-based image classification models have been proved to be valid for the pneumonia classification using chest X-ray images, helping physicians to diagnose and treat the disease more effectively. However, the vulnerability of deep neural networks was confirmed by researchers through the injection of tiny perturbations which is imperceptible to humans. These adversarial samples become a major threat to the medical safety system, especially in the disease detection field. In this regard, we made some experiments to attack chest X-ray images to investigate the efficiency of two types of attack methods with the sign and no-sign operators. Fast Gradient Sign Method (FGSM), Basic Iterative Method (BIM), and Projected Gradient Descent (PGD) were selected and transformed into no-sign attack methods to analyze their effectiveness on white-box and black-box testing. We theoretically and experimentally confirmed the alternative no-sign attack methods were more efficient. © 2022 IEEE.
ABSTRACT
The jelly from achenes of Ficus pumila var. awkeotsang (FPAA) is a famous beverage ingredient in Taiwan. In this work, ficumarin (1), a new compound was obtained from its twigs (FPAT) and elucidated with comprehensive spectroscopic data. The biosynthetic origin was proposed from the p-coumaroyl-CoA pathway. Alloxanthoxyletin, betulinic acid, and catechin were identified as the major and active constituents responsible for relieving neutrophilic inflammation by FPAT. Among them, the most potent alloxanthoxyletin was found to interact with PRO350 and GLU377 of human INOSOX. Further, Nrf2 activating capacity of the FPAT fraction and its coumarins was confirmed. With the analysis of LC-MS/MS data and feature-based molecular networking, coumarins were found as the dominant and responsible components. Notably, alloxanthoxyletin increased Nrf2 expression by up to 816.8 +/- 58% due to the interacting with the VAL561, THR560 and VAL420 residues of 5FNQ protein. COVID-19 Docking Server simulation indicated that pyranocoumarins would promisingly interfere with the life cycle of SARS-CoV-2. FPAT was proven to exert. Copyright © 2022 Taiwan Food and Drug Administration.
ABSTRACT
Background: There is increasing use of social media as a platform to discuss research and educate. An article's impact can be assessed through the Altmetric Attention score (AAS), which considers the volume of social media mentions (Twitter, Facebook, Wikipedia, policy, etc), and the PlumX Impact score, which incorporates interactions on these platforms and citations. COVID-19 has encouraged novel literature in oncology, and these metrics may holistically evaluate the immediate impact of articles in addition to gradual accrual of citations. We explored the relationship between traditionally used bibliometrics (citations, impact factor) and new bibliometrics (AAS, PlumX) of the top 100 trending articles on cancer and COVID-19. Methods: The 100 articles with highest AAS featuring keywords “cancer” and “COVID-19” between March 1, 2019 and January 15, 2022 were identified via Altmetric explorer. AAS, journal, social media mentions, open access status and other characteristics were collected. Scopus database was utilized to identify PlumX scores and citation count. Analysis included Spearman correlation coefficients and ANOVA. Results: Of the 100 articles, 64% were original investigations, 18% editorials/perspectives, 6% guidelines/consensus articles and remaining article types < 6% each. Original investigations comprised of 41% retrospective cohort, 33% cross-sectional, 20% prospective cohort, and remainder < 4% each. Most articles were open access (91%), from cancer-focused journals (77%), and based in North America (36%);25% were in Europe, 24% multi-continental, and remainder < 8% each. Most publications were in 2020 (56%) and 2021 (40%). AAS and PlumX did not correlate with number of citations or impact factor. Open access publications were associated with greater PlumX (p = 0.033) compared to closed access;this was not seen with AAS. ANOVA showed greater AAS in Australian articles (p =.004) and greater PlumX in North American articles (p =.04). Article type or publication year did not impact AAS and PlumX. Conclusions: In our analysis, Altmetrics and PlumX did not correlate to traditional bibliometrics (citation count, impact factor) in cancer and COVID-19 articles. This suggests that these tools may be complimentary rather than predictive of citations. However, this may change given likely insufficient time for citations to accrue for 2021 studies. There were more editorials/perspective articles compared to similar studies in other specialties, suggesting greater impact of such articles in oncology during COVID-19;this is perhaps due to reliance on expert opinion given paucity of data. Additionally, we noted that PlumX benefits from open access status. Overall, as the use of social media for research dissemination grows, researchers and journal editors may employ alternative metrics to better understand ways to increase the influence of oncology literature during the pandemic.
ABSTRACT
Background: Nurse is a high-risk groups work fatigue feeling, which seriously affects the quality of conventional work efficiency and bureden pressures for contradiction between nurses and patients especially during the COVID-19 pandemic.Normalized epidemic prevention and control during the preview triage nurse need to all patients to the hospital and the accompanying personnel carries on the preliminary screening.COVID-19 fxed point hospital preview triage nurse with an infected person contact, more prone to anxiety,depression, results in the decrease of efficiency, to treat the service object formulation work sense of fatigue performance, etc. Objectives: To explore the influencing factors of work burnout of pre-test and triage nurses under normal epidemic prevention and control. Methods: A total of 110 pre-test and triage nurses from 4 Grade-A hospitals in Shanxi Province were enrolled in this study. The general data questionnaire, Nurse Job Burnout Scale, Pittsburgh Sleep Quality Index Scale, Self-Rating Anxiety Scale and Self-Rating Depression Scale were investigated towork burnout of pre-examination and triage nurses. Comparison between groups using two Independent sample t-test and single factor variance analysis. Multiple regression were applied to analysis factors affecting nurse fatigue feeling dimensions by SPSS22.0. P values<0.05 were considered signifcant. Results: As shown in Table 1, different professional title, department, and the sleep quality of preview triage nurses emotional exhaustion dimension com-parison(P<0.001), different department nurses to personalized level dimension comparison(P<0.05), nurse personal accomplishment dimension comparison of different cultural levels(P<0.05). Professional title, working department, sleep quality and educational level were the influencing factors of job burnout of pretest and triage nurses. Conclusion: In the COVID-19 epidemic, managers should pay more attention to the main factors that affect the sense of exhaustion of pre-test and triage nurses, and take targeted intervention measures to alleviate the sense of exhaustion of nurses, so as to ensure the safety of nursing.
ABSTRACT
OBJECTIVE: The COVID-19 pandemic has influenced regular medical procedures and health-seeking behaviors. In this study, we aimed to investigate the influence of the COVID-19 pandemic on the presentation and prognosis of acute ischemic stroke (AIS) patients in county-level stroke centers. PATIENTS AND METHODS: We retrospectively collected AIS patients during the strict lockdown period (January 24, 2020, to March 27, 2020) and the corresponding "new normal" period (2021) of the COVID-19 pandemic. Patients seen during the same timeframe in 2019 were enrolled as controls. Statistical analysis was conducted to compare the clinical characteristics of AIS patients who presented during the lockdown and new normal periods and those who presented during the pre-COVID-19 pandemic period. RESULTS: A total of 134 AIS patients presented during the lockdown period (the 2020 group), 207 patients in the pre-COVID-19 period (the 2019 group) and 201 patients in the "new normal" period (the 2021 group). Compared to the 2019 group, there was approximately 1/3 reduction in the number of patients who presented during the lockdown period, while the number of patients who received IVT or EVT was similar between the two groups. The number of patients, baseline characteristics, workflow intervals and clinical outcomes presented during the "new normal" period were similar between the 2019 and 2021 groups. Logistic regression showed that lockdown or new normal status were not risk factors associated with a poor outcome at 90 days. CONCLUSIONS: In county-level city stroke centers, the COVID-19 lockdown resulted in a reduction in the number of patients with AIS admitted to the hospital but had no effect on patients treated with IVT or EVT. Lockdown or new normal status did not influence the prognosis of AIS patients.
Subject(s)
COVID-19 , Ischemic Stroke , Stroke , COVID-19/epidemiology , Communicable Disease Control , Humans , Ischemic Stroke/diagnosis , Ischemic Stroke/epidemiology , Pandemics , Prognosis , Retrospective Studies , Stroke/epidemiology , Stroke/therapyABSTRACT
The devastating, ongoing Covid-19 epidemic has led to many students resorting to online education. In order to better guarantee the quality, online education faces severe challenges. There is an important part of online education referred to as Knowledge Tracing (KT). The objective of KT is to estimate students’ learning performance using a series of questions. It has garnered widespread attention ever since it was proposed. Recently, an increasing number of research efforts have concentrated on deep learning (DL)-based KT attributing to the huge success over traditional Bayesian-based KT methods. Most existing DL-based KT methods utilize Recurrent Neural Network and its variants, i.e. Long Short-Term Memory (LSTM), Gated Recurrent Unit (GRU) etc. Recurrent neural networks are good at modeling local features, but underperforms at long sequence modeling, so the attention mechanism is introduced to make up for this shortcoming. In this paper, we introduce a DL-based KT model referred to as Convolutional Attention Knowledge Tracing (CAKT) utilizing attention mechanism to augment Convolutional Neural Network (CNN) in order to enhance the ability of modeling longer range dependencies. © 2022, IFIP International Federation for Information Processing.
ABSTRACT
BACKGROUND: Persons living with dementia (PLWD) and family care partners (CPs) want to improve their health, maintain independence, and enhance well-being. Multi-domain interventions towards this goal are needed, but few are available and fewer were co-created with PLWD, CPs, and program providers. The objective of the DELIGHT project is to use a participatory approach to co-design a feasible, effective multi-domain intervention (the DELIGHT program) that meets the health and well-being goals of PLWD and CPs. METHOD: Using a participatory approach, the DELIGHT project is guided by a core team of researchers, PLWD, CPs, and an Alzheimer Society representative. The co-design team included the core team and additional PLWD/CPs, exercise professionals, dietitians, health care professionals, and community service providers (n=29). Due to COVID-19, research team meetings have been virtual since May 2020. The co-design was planned for four in-person, half-day sessions but was transitioned to six online, 1.5-hour sessions, using small breakout rooms for discussion. The co-design meetings focused on identifying target population, key outcomes of the program and developing program components and structure. During co-design meetings, two or three guiding questions were set to focus discussion on a specific topic (e.g., exercise). The final co-design session focused on the overall structure of the DELIGHT program. The core team then reflected on co-design discussions and decisions and made final decisions on program structure. Program resources were iteratively designed with the core team, co-design team, and other external stakeholders (including an illustrator). RESULT: The DELIGHT program is designed to promote well-being among PLWD and CP. Engagement soon after diagnosis is a goal. The program will meet twice per week for one hour of exercise and thirty minutes of facilitated discussion/education with a healthy snack and social engagement. Education will focus on healthy eating, sleeping well, mental well-being, social connection, and physical activity. Program resources and manual are in development. CONCLUSION: The DELIGHT program was co-created by PLWD, CPs, researchers, and community stakeholders to meet the health and well-being goals of PLWD and CPs. The on-line and in-person program options will be piloted and evaluated in fall 2021. © 2021 the Alzheimer's Association.
ABSTRACT
BACKGROUND: Engaged research involves stakeholders as active partners in the research process, not just as research participants. Engaged dementia research can improve the relevance and quality of research, empower persons living dementia (PLWD) and family care partners, and acknowledge their expertise gained through lived experience. Conducting engaged research is challenging during COVID-19 when in-person interactions are difficult or impossible. The Dementia Lifestyle Intervention for Getting Health Together (DELIGHT) project used an online, engaged research approach to co-design the DELIGHT program, a 12-week program to support the health and well-being goals of PLWD and care partners. Here, we used mixed-methods to evaluate the DELIGHT co-design process, its alignment with an Authentic Partnership approach, and experiences, satisfaction, and suggestions for future online co-design processes. METHOD: The DELIGHT project engaged 29 people in the co-design process during Summer 2020, including PLWD, care partners, service/program providers, healthcare providers, and researchers. The co-design team met over six, 1.5-hour online meetings (via Zoom) to develop the program. Although the co-design process is on-going, evaluation focused on this first phase of the co-design process. A 17-item survey assessed alignment with an Authentic Partnerships approach. Focus groups and interviews used a semi-structured guide to assess experiences, satisfaction, and suggestions for future on-line co-design. RESULT: Surveys were completed by 11 co-design members, and 11 co-design members participated in interviews or focus groups (not all completed both). Initial analysis of survey results indicates co-design members felt respected and safe in the co-design process, felt their perspectives and opinions were valued, and valued the contributions of other members (100% agreed or strongly agreed). All survey respondents felt they gained knowledge and strategies for living well with dementia during the co-design process. All survey respondents also strongly agreed that the DELIGHT program, when implemented, will have a positive impact on PLWD and care partners. Analysis of interviews/focus groups is ongoing and will be available in Spring 2021. CONCLUSION: Co-design members expressed high satisfaction with the process and felt their experiences were valued and heard. All members expressed a strong belief that the program developed will benefit PLWD and care partners. © 2021 the Alzheimer's Association.
ABSTRACT
Background: Ibrutinib (IBR) and venetoclax (VEN) combination is a highly effective therapy for patients (pts) with CLL (Jain, NEJM 2019;Wierda, ASH 2020;Kater, EHA 2021). We previously reported results of the first-line cohort of a phase II trial of combined IBR and VEN for high-risk pts with CLL (Jain, NEJM 2019;Jain, JAMA Oncology 2021). Here we report updated data for these pts with focus on MRD. Methods: Pts with previously untreated CLL meeting IWCLL treatment criteria were enrolled. All pts had at least one high-risk feature: del(17p), mutated TP53, del(11q), unmutated IGHV, or age ≥65 years (yrs). Pts received IBR 420 mg daily for 3 cycles followed by addition of VEN (weekly dose-escalation to 400mg daily). Combined therapy was given for 24 cycles (28 days/cycle). Pts with bone marrow (BM) undetectable MRD (U-MRD) (flow cytometry;sensitivity 10 -4) at 24 cycles of combined therapy discontinued both VEN and IBR;MRD+ pts continued IBR. A trial amendment allowed an additional 12 cycles of combined VEN and ibrutinib for pts who remained BM MRD+ after Cycle 24. Response assessments were performed using BM and CT imaging studies (2008 IWCLL criteria). U-MRD was defined as <0.01%;low MRD+ 0.01% to <1%;high MRD+ ≥1%. Progression-free survival (PFS) was assessed as the time from the start of study drug to CLL progression, Richter transformation, or death from any cause. Blood MRD was monitored every 6 months in pts off treatment or on ibrutinib monotherapy beyond 24 cycles of combined treatment. Results: A total of 80 pts were enrolled. Baseline characteristics are shown in Table 1. The median follow-up was 44.1 months. Five pts came off study during 1 st 3 cycles of IBR monotherapy;75 pts initiated VEN. We previously reported that after 12 cycles of the combination, 45/80 (56%) achieved BM U-MRD remission;24/80 (30%) were BM MRD-positive (low MRD+, n=19;high MRD+, n=5). After 24 cycles of the combination, 53/80 (66%) achieved BM U-MRD remission;14/80 (17%) were BM MRD+ (low MRD+, n=13;high MRD+, n=1). Overall, 60/80 (75%) achieved BM U-MRD as the best response. Updated PFS is provided in Figure 1. Of the 53 pts who were BM U-MRD at the end of cycle 24 of the combination, 52 pts had a subsequent blood MRD assessment done in follow-up (1 missed due to COVID-19);51/53 discontinued all therapy, 2 pts continued IBR per treatment physician discretion. With a median time of 18.4 months post Cycle 24, 8 pts had recurrence of blood MRD (defined as MRD ≥ 0.01% in 2 consecutive visits) in follow-up with 1 pt with CLL progression. The sole pt with CLL progression had mutated IGHV with del(11q) and NOTCH1 mutation. The pt had delayed achievement of BM U-MRD with the pt achieving U-MRD for the first time at the end of Cycle 24 of combined therapy. She was noted to have disease progression 22 months off therapy;BTK or PLCG2 mutation were not detected and the patient is currently in clinical remission on acalabrutinib. The time to MRD conversion for these 53 pts is shown in Figure 2. There were 14 pts who were BM MRD+ at the end of cycle 24 of the combination (low MRD+, n=13;high MRD+, n=1). The only pt with high-MRD+ at end of cycle 24 was noted to have Richter transformation at that time. The remaining 13 pts (all low MRD+ in BM, range 0.01-0.56%) continued IBR monotherapy. With a recent trial amendment, MRD+ pts after Cycle 24 could get 12 additional cycles of venetoclax;9/13 pts have resumed VEN. 6/9 pts have achieved U-MRD remission. 2 pts had Richter transformation and 3 pts have died (Jain, JAMA Oncology 2021). Conclusions: We report long term follow-up of combined IBR and VEN in first-line CLL. Remissions were durable with some pts having recurrence of blood MRD in follow-up, which may be an early indicator of relapse. In a small subset of the pts with BM MRD+ disease at 24 cycles of combined therapy, additional VEN appears to lead to U-MRD remission in majority of the pts. Whether this will lead to improved long-term PFS remains to be determined. [Formula presented] Disclosures: Jain: TG Therapeutics: Honoraria;Beigene: Honoraria;Janssen: Honoraria;Fate Therapeutics: Research Funding;Aprea Therapeutics: Research Funding;Precision Biosciences: Honoraria, Research Funding;Incyte: Research Funding;Adaptive Biotechnologies: Honoraria, Research Funding;Cellectis: Honoraria, Research Funding;ADC Therapeutics: Honoraria, Research Funding;Servier: Honoraria, Research Funding;Pfizer: Research Funding;Bristol Myers Squibb: Honoraria, Research Funding;AstraZeneca: Honoraria, Research Funding;Genentech: Honoraria, Research Funding;AbbVie: Honoraria, Research Funding;Pharmacyclics: Research Funding. Thompson: AbbVie: Other: Institution: Advisory/Consultancy, Honoraria, Research Grant/Funding;Amgen: Other: Institution: Honoraria, Research Grant/Funding;Genentech: Other: Institution: Advisory/Consultancy, Honoraria, Research Grant/Funding;Adaptive Biotechnologies: Other: Institution: Advisory/Consultancy, Honoraria, Research Grant/Funding, Expert Testimony;Pharmacyclics: Other: Institution: Advisory/Consultancy, Honoraria, Research Grant/Funding;Janssen: Consultancy, Honoraria;Gilead: Other: Institution: Advisory/Consultancy, Honoraria. Ferrajoli: BeiGene: Other: Advisory Board, Research Funding;Janssen: Other: Advisory Board;AstraZeneca: Other: Advisory Board, Research Funding. Burger: Novartis: Other: Travel/Accommodations/Expenses, Speakers Bureau;TG Therapeutics: Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau;Janssen: Consultancy, Other: Travel/Accommodations/Expenses, Speakers Bureau;Beigene: Research Funding, Speakers Bureau;Pharmacyclics LLC: Consultancy, Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau;Gilead: Consultancy, Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau;AstraZeneca: Consultancy. Borthakur: GSK: Consultancy;ArgenX: Membership on an entity's Board of Directors or advisory committees;University of Texas MD Anderson Cancer Center: Current Employment;Protagonist: Consultancy;Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees;Astex: Research Funding;Ryvu: Research Funding;Takeda: Membership on an entity's Board of Directors or advisory committees. Takahashi: Symbio Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees;Novartis: Consultancy;Celgene/BMS: Consultancy;GSK: Consultancy. Sasaki: Daiichi-Sankyo: Membership on an entity's Board of Directors or advisory committees;Pfizer: Membership on an entity's Board of Directors or advisory committees;Novartis: Consultancy, Research Funding. Kadia: Cellonkos: Other;Aglos: Consultancy;Dalichi Sankyo: Consultancy;AbbVie: Consultancy, Other: Grant/research support;BMS: Other: Grant/research support;Amgen: Other: Grant/research support;Cure: Speakers Bureau;Jazz: Consultancy;Genentech: Consultancy, Other: Grant/research support;Liberum: Consultancy;Novartis: Consultancy;Pfizer: Consultancy, Other;Pulmotech: Other;Sanofi-Aventis: Consultancy;AstraZeneca: Other;Astellas: Other;Genfleet: Other;Ascentage: Other. Konopleva: Sanofi: Other: grant support, Research Funding;Cellectis: Other: grant support;Calithera: Other: grant support, Research Funding;KisoJi: Research Funding;Agios: Other: grant support, Research Funding;Ascentage: Other: grant support, Research Funding;AbbVie: Consultancy, Honoraria, Other: Grant Support, Research Funding;Ablynx: Other: grant support, Research Funding;Stemline Therapeutics: Research Funding;Eli Lilly: Patents & Royalties: intellectual property rights, Research Funding;AstraZeneca: Other: grant support, Research Funding;Rafael Pharmaceuticals: Other: grant support, Research Funding;Genentech: Consultancy, Honoraria, Other: grant support, Research Funding;F. Hoffmann-La Roche: Consultancy, Honoraria, Other: grant support;Forty Seven: Other: grant support, Research Funding;Novartis: Other: research funding pending, Patents & Royalties: intellectual property rights;Reata Pharmaceuticals: Current holder of stock options in a privately-held company, Patents & Royalties: intellectual property rights. Alvarado: BerGenBio: Research Funding;Jazz Pharmaceuticals: Research Funding;Astex Pharmaceuticals: Research Funding;Sun Pharma: Consultancy, Research Funding;MEI Pharma: Research Funding;FibroGen: Research Funding;Daiichi-Sankyo: Research Funding;CytomX Therapeutics: Consultancy. Yilmaz: Pfizer: Research Funding;Daiichi-Sankyo: Research Funding. DiNardo: Notable Labs: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees;Novartis: Honoraria;Takeda: Honoraria;Celgene, a Bristol Myers Squibb company: Honoraria, Research Funding;Forma: Honoraria, Research Funding;AbbVie: Consultancy, Research Funding;GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees;Bristol Myers Squibb: Honoraria, Research Funding;ImmuneOnc: Honoraria, Research Funding;Agios/Servier: Consultancy, Honoraria, Research Funding;Foghorn: Honoraria, Research Funding. Bose: Kartos Therapeutics: Honoraria, Research Funding;Sierra Oncology: Honoraria;Novartis: Honoraria;Constellation Pharmaceuticals: Research Funding;NS Pharma: Research Funding;Celgene Corporation: Honoraria, Research Funding;Blueprint Medicines: Honoraria, Research Funding;Pfizer: Research Funding;Promedior: Research Funding;Astellas: Research Funding;Incyte Corporation: Honoraria, Research Funding;BMS: Honoraria, Research Funding;CTI BioPharma: Honoraria, Research Funding. Pemmaraju: Blueprint Medicines: Consultancy;LFB Biotechnologies: Consultancy;Novartis Pharmaceuticals: Consultancy, Other: Research Support, Research Funding;ASCO Leukemia Advisory Panel: Membership on an entity's Board of Directors or advisory committees;Dan's House of Hope: Membership on an entity's Board of Directors or advisorycommittees;Roche Diagnostics: Consultancy;MustangBio: Consultancy, Other;Affymetrix: Consultancy, Research Funding;Samus: Other, Research Funding;ImmunoGen, Inc: Consultancy;ASH Communications Committee: Membership on an entity's Board of Directors or advisory committees;Aptitude Health: Consultancy;Plexxicon: Other, Research Funding;Springer Science + Business Media: Other;Protagonist Therapeutics, Inc.: Consultancy;HemOnc Times/Oncology Times: Membership on an entity's Board of Directors or advisory committees;Clearview Healthcare Partners: Consultancy;Abbvie Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding;CareDx, Inc.: Consultancy;Sager Strong Foundation: Other;Daiichi Sankyo, Inc.: Other, Research Funding;Incyte: Consultancy;Stemline Therapeutics, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding;Bristol-Myers Squibb Co.: Consultancy;DAVA Oncology: Consultancy;Pacylex Pharmaceuticals: Consultancy;Celgene Corporation: Consultancy;Cellectis S.A. ADR: Other, Research Funding. Jabbour: Amgen, AbbVie, Spectrum, BMS, Takeda, Pfizer, Adaptive, Genentech: Research Funding. Wang: Stemline Therapeutics: Honoraria. Kantarjian: Taiho Pharmaceutical Canada: Honoraria;Precision Biosciences: Honoraria;Immunogen: Research Funding;Daiichi-Sankyo: Research Funding;Jazz: Research Funding;BMS: Research Funding;AbbVie: Honoraria, Research Funding;Pfizer: Honoraria, Research Funding;Novartis: Honoraria, Research Funding;NOVA Research: Honoraria;KAHR Medical Ltd: Honoraria;Ipsen Pharmaceuticals: Honoraria;Astra Zeneca: Honoraria;Astellas Health: Honoraria;Aptitude Health: Honoraria;Amgen: Honoraria, Research Funding;Ascentage: Research Funding. Wierda: Juno Therapeutics: Research Funding;AstraZeneca: Research Funding;Xencor: Research Funding;Janssen: Research Funding;Loxo Oncology, Inc.: Research Funding;Cyclacel: Research Funding;Oncternal Therapeutics, Inc.: Research Funding;Miragen: Research Funding;KITE Pharma: Research Funding;Sunesis: Research Funding;Gilead Sciences: Research Funding;Acerta Pharma Inc.: Rese rch Funding;Pharmacyclics LLC, an AbbVie Company: Research Funding;Karyopharm: Research Funding;Genentech: Research Funding;GSK/Novartis: Research Funding;Genzyme Corporation: Consultancy;AbbVie: Research Funding. OffLabel Disclosure: The combination of ibrutinib and venetoclax is not FDA approved
ABSTRACT
Background: As the COVID-19 pandemic has heightened the importance of online recruitment, program websites (PW) have become increasingly instrumental for applicants to evaluate fellowship opportunities. A robust pediatric gastroenterology PW can aid applicants by illustrating a program's mission and educational opportunities. Amongst the various criteria that prospective applicants assess, perceived inclusivity and physician well-being are essential components contributing to program culture and positively influence ranking decisions. We conducted a comprehensive audit of pediatric gastroenterology PWs to identify potential opportunities to improve PW content, better serve applicants, and ultimately facilitate a more informed match process. Methods: This study evaluated 2020-2021 ACGME accredited pediatric gastroenterology PWs for the presence of binary informational, diversity, and wellness categories. We assessed the presence of 28 informational variables derived from previously published website analyses with added specialty-specific variables. Our study also considered three categories for evaluating diversity and inclusion that were adapted from inclusive online graduate medical education recruitment strategies. Wellness content was evaluated using four categories adapted from wellness curriculums and pertinent categories in previously published studies. We defined websites with 70% or more of the investigated 28 informational categories as “comprehensive websites,” a threshold used in prior studies. GraphPad software (GraphPad Prism 7, GraphPad Software, San Diego, CA) was utilized for all univariate analyses using Spearman Correlation's test, with statistical significance defined as p-value <0.05. Results: Of the 64 programs which had functional fellowship websites, 48.4% had a “comprehensive website.” Overall, programs on average filled 59.7% of all categories. 46.9% of the programs had information pertaining to at least one of the three assessed diversity categories and 56.3% of the programs had content relating to at least one of the four wellness categories. The prevalence of each category is shown in Figure 1. We found a positive association between having a more complete website and more diversity-identified website (p=0.024) or a wellness-identified website (p=0.005). Discussion & Conclusion: In an increasingly virtual world, PWs serve as an applicant's first impression, influencing the perception of a program's key initiatives. While our results suggest that PWs vary greatly in comprehensiveness, overall, pediatric gastroenterology PWs are lacking in all three of our evaluated categories. Our study found that more complete websites also tend to fill more of the diversity and wellness categories. This trend suggests that a progression towards a more complete PW includes both diversity and wellness components, rather than viewing them as separate categories. The incomplete nature of pediatric gastroenterology PWs is notable. Traditional in-person recruitment strategies allowed applicants to explore hospital facilities, interact with diverse faculty, and observe colleague camaraderie. Hence, in the era of heightened virtual recruitment, it would be beneficial for programs to effectively translate their initiatives to digital mediums. It behooves programs to highlight efforts they have made toward these important areas, both to represent themselves accurately and better cater to the interests of their prospective applicants. Ultimately, PWs are cost-effective tools in recruitment for pediatric gastroenterology fellowships and should be optimized to capture key tenets of a program's culture. By doing so, programs can strategically align with the interests and values of prospective applicants, empowering applicants to make more informed decisions that foster better matches.
ABSTRACT
Objectives: To evaluate the impact of COVID-19 pandemic on the mental health of Malaysian university and pre-university students, especially after the shift to online academic activities, following almost one year of experiencing the pandemic Methods: A cross-sectional online survey was conducted among Malaysian preuniversity and university students, nationwide, using perceived stress scale-10 questionnaire and another validated 11-construct questionnaire. Key findings: The online questionnaires were filled out by 383 Malaysian pre-university and university students. About 40% of the respondents reported moderate to severe level of loneliness and social isolation. There was a significant correlation between suicidal thoughts and the social isolation. The prevalence of moderate to severe suicidal thoughts (14% of the respondents) was more than the reported prevalence before COVID-19 pandemic. The residential state, gender and ethnicity of the respondents did not show an association with depressive and suicidal thoughts of the respondents. Conclusion: Loneliness and feeling social isolation were the most prevalent problems, as reported by the students. Suicidal Thoughts are more prevalent, compared to pre-COVID-19 reports. The educators and institution managers must seek for appropriate methods to address the critical condition.